MHM Magazine

Introduction Adolescent depression, a pressing public health issue, affects 3.5% to 8% of young people, with a lifetime prevalence nearing 20% by the end of adolescence. This condition is associated with high rates of relapse and significant developmental disruption. Adolescent depression is associated with significant morbidity and mortality which includes: • Poor social and scholastic functioning • Unplanned pregnancy • Increased risk of physical illness and substance abuse • Increased risk of suicide, alarmingly it is the second leading cause of death in the 15-24-year age group The Current Treatment for Adolescent Depression The current treatment available for depression include: SSRI’s (Selective Serotonin Reuptake Inhibitors) which are effective for moderate to severe depression and quality evidence based psychotherapy are also reasonable options for adolescents with depression. Dr Alicia Porter Child Psychiatrist Charlotte Maxeke Johannesburg Academic Hospital THE USE OF KETAMINE IN ADOLESCENTS WITH TREATMENT RESISTANT DEPRESSION: WHERE ARE WE AND WHAT DOES THE CURRENT EVIDENCE SAY? MHM | 2024 | Volume 11 | Issue 2 | The Use of Ketamine in Adolescents with Treatment Resistant Depression: Where are we and what does the current evidence say? MHM 10 | MENTAL HEALTH MATTERS | 2024 | I sue 2 H